BioCentury
ARTICLE | Clinical News

ALVAC HIV vaccine: Phase III data

September 28, 2009 7:00 AM UTC

Data from the U.S. Army Surgeon General-sponsored, double-blind, Thai Phase III RV144 trial in 16,402 adult volunteers showed that Sanofi Pasteur S.A.'s ALVAC HIV vaccine boosted by the AIDSVAX B/E gp120 vaccine lowered the rate of HIV infection by 31.1% vs. placebo at 3 years (51 vs. 74 infections, p=0.04). The vaccine regimen was well tolerated. Subjects received ALVAC HIV or placebo at enrollment and at months 1, 3 and 6. The AIDSVAX B/E booster or placebo was administered at months 3 and 6. ...